Copyright
©The Author(s) 2021.
World J Gastrointest Oncol. Dec 15, 2021; 13(12): 2161-2179
Published online Dec 15, 2021. doi: 10.4251/wjgo.v13.i12.2161
Published online Dec 15, 2021. doi: 10.4251/wjgo.v13.i12.2161
Table 2 Clinical and demographic characteristics of the study population
| Characteristics | n (%) |
| No. of patients | 413 |
| Age, median (IQR), yr | 61 (54-67) |
| BMI, median (IQR), (kg/m2) | 23.04 (20.83-25.10) |
| Male | 304 (73.61) |
| ASA score | |
| 1 | 102 (24.70) |
| 2 | 255 (61.74) |
| 3 | 56 (13.56) |
| ECOG | |
| 0 | 229 (55.45) |
| 1 | 168 (40.68) |
| 2 | 16 (3.87) |
| Location | |
| Upper | 166 (40.19) |
| Middle | 51 (12.35) |
| Lower | 170 (41.16) |
| Diffuse | 26 (6.30) |
| Diameter (cm) | 3.0 (1.5-4.0) |
| Differentiation | |
| Well | 27 (6.54) |
| Moderate | 176 (42.86) |
| Poor | 209 (50.61) |
| Mucinous or signet cell | 85 (20.58) |
| LVI | 132 (31.96) |
| Cycles of treatment | 2 (2-3) |
| ypT | |
| ypT0 | 37 (8.96) |
| ypT1 | 25 (6.05) |
| ypT2 | 55 (13.32) |
| ypT3 | 66 (15.98) |
| ypT4 | 230 (55.69) |
| ypN | |
| N0 | 169 (40.92) |
| N1 | 64 (15.50) |
| N2 | 70 (16.95) |
| N3 | 110 (26.63) |
| ypStage | |
| pCR | 32 (7.75) |
| I | 57 (13.80) |
| II | 116 (28.09) |
| III | 208 (50.36) |
| Total gastrectomy | 180 (43.58) |
| Regimen | |
| Platin-based | 364 (88.14) |
| Taxol-based | 25 (6.05) |
| Triplet | 24 (5.81) |
| Adjuvant chemotherapy | 308 (74.58) |
| Postoperative complications | |
| Grade 0-1 | 277 (67.07) |
| Grade 2 | 78 (18.89) |
| Grade 3-4 | 58 (14.04) |
| JGCA2017-TRG | |
| Grade 3 (no residual) | 36 (8.72) |
| Grade 2b (< 10%) | 39 (9.44) |
| Grade 2a (10%-33%) | 29 (7.02) |
| Grade 1b (34%-66%) | 78 (18.89) |
| Grade 1a (67%-99%) | 205 (49.64) |
| Grade 0 (no response) | 26 (6.30) |
| JGCA-TRG | |
| Grade 3 (no residual) | 36 (8.72) |
| Grade 2 (< 33%) | 68 (16.46) |
| Grade 1b (34%-66%) | 78 (18.89) |
| Grade 1a (67%-99%) | 205 (49.64) |
| Grade 0 (no response) | 26 (6.30) |
| Becker-TRG | |
| 1a (no residual) | 36 (8.72) |
| 1b (< 10%) | 39 (9.44) |
| 2 (10%-50%) | 65 (15.74) |
| 3 (> 50%) | 273 (66.10) |
| AJCC-TRG | |
| 0 (complete response) | 36 (8.72) |
| 1 (moderate response) | 48 (11.62) |
| 2 (minimal response) | 89 (21.55) |
| 3 (poor response) | 240 (58.11) |
| Mandard-TRG | |
| 1 (complete response) | 36 (8.72) |
| 2 (Fibrosis + scattered tumor cells) | 48 (11.62) |
| 3 (Fibrosis predominance + tumor cells) | 89 (21.55) |
| 4 (Tumor cells preponderance + fibrosis) | 214 (51.82) |
| 5 (No response) | 26 (6.30) |
- Citation: Liu ZN, Wang YK, Zhang L, Jia YN, Fei S, Ying XJ, Zhang Y, Li SX, Sun Y, Li ZY, Ji JF. Comparison of tumor regression grading systems for locally advanced gastric adenocarcinoma after neoadjuvant chemotherapy. World J Gastrointest Oncol 2021; 13(12): 2161-2179
- URL: https://www.wjgnet.com/1948-5204/full/v13/i12/2161.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v13.i12.2161